February 27, 2008 13:00 ET

Going Global and the Business of Outsourcing, More at iiBIG Boston Forum

NEW YORK, NY--(Marketwire - February 27, 2008) - Multinational interest and investment in the global pharmaceutical industry is at an all-time high and competition is heating up. Big pharma is pumping in more resources into outsourcing and offshoring. Drug safety issues, threat from biogenerics, stricter protocols for APIs and pharmacovigilance issues question some existing models and frameworks. To reverse the decline in new drug approvals, more development candidates and new delivery systems are needed now more than ever. Pressures on the cost of healthcare require ever greater cost efficiency in R&D. Outsourcing collaborations at every stage of discovery and development are helping to meet these growing demands, and are driving innovation and growth in the industry. Business relationships in outsourcing must manage priorities, costs, timelines and intellectual property.

iiBIG's 2008 BioPharma Outsourcing: Partnerships with CROs and Other Service Providers forum, scheduled for March 25-26, 2008 in Boston, MA will review who is doing what -- and what is next -- in this exciting area of partnership and collaboration.

Distinguished Speaker Roster Includes:

--  Diana M. Galer Ph.D., VP, Strategic Management Group, Pfizer Global
    Research & Development
--  Mark Tracy, Senior Director, Pharmaceutical Operations, Alnylam
--  RoseAnn Price, Alliance Management, Amgen
--  Mel Sorensen, M.D., President & CEO, Ascenta Therapeutics, Inc.
--  Ahsan Awan, JD, MBA, CRCP, Global CINRG, Inc.
--  Gur Roshwalb, MD, VP & Senior Analyst Health Care, Piper Jaffray & Co.
--  Han Gunn, Preclinical Director, Department of Pharmacokinetics & Drug
    Metabolism, Amgen
--  Partha S. Ray, MD, CEO, IndusPharma Consulting Group
--  Michael Palladino, PhD, Senior VP, CTO, & Scientific Co-Founder,
    Nereus Pharmaceuticals
--  Steve J. Bannister, PhD, Chief Scientific Officer, Xcelience, LLC
--  Judd Berman, PhD., Chief Scientific Officer, Dalton Medicinal
--  Zhengming (Jimmy) Chen, PhD, Senior Director, Chemistry and CMC, DOV
    Pharmaceutical, Inc.
--  John Lemelan, General Partner, Riverside Partners
--  Dean Wilson, PhD, Research Fellow, Vertex Pharmaceuticals
--  John Maclennan, PhD, Director, Business Development, Wolfe
    Laboratories, Inc.

For complete agenda details:

For complete list of speakers, detailed agenda, and to register:

Contact Information